Depressive Disorder Clinical Trial
Official title:
An Open Label Trial of Inhaled N,N-Dimethyltryptamine in Patients With Partial Response in Depression.
Verified date | May 2024 |
Source | Universidade Federal do Rio Grande do Norte |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to evaluate the acute and subacute effects of an inhaled N, N-Dimethyltryptamine (DMT) in patients with partial response in depression.
Status | Completed |
Enrollment | 14 |
Est. completion date | March 30, 2024 |
Est. primary completion date | January 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Patients in current treatment for depression with a partial response. Exclusion Criteria: - heart failure - liver failure - kidney failure - uncontrolled high blood pressure - history of heart rhythm disorders - history of valvular heart disease - history of chronic obstructive pulmonary disease (COPD) - active or in treatment for bronchial asthma - severe obesity - coagulation disorders - clinical evidence or history of increased intracranial - clinical evidence or history of cerebrospinal pressure - history or reports of epilepsy - severe neurological disease - pregnancy - reported or clinically recognized thyroid disorders - diagnosis or family suspicion of genetic monoamine deficiency oxidase - previous adverse response to psychedelic substances - symptoms or family members with a present or past psychotic disorder - dissociative identity disorder - bipolar affective disorder - prodromal symptoms of schizophrenia - problematic use or abuse of alcohol or other psychoactive substances (except tobacco) - acute or subacute risk of suicide - acute flu symptoms - symptoms of airway infection - contact with a confirmed case of COVID-19 (SARS-CoV-2) in the last 7 days |
Country | Name | City | State |
---|---|---|---|
Brazil | Hospital Universitário Onofre Lopes | Natal | RN |
Lead Sponsor | Collaborator |
---|---|
Universidade Federal do Rio Grande do Norte |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Systolic Blood Pressure | Assessed 7 times on each session | up to 2 hours | |
Other | Diastolic Blood Pressure | Assessed 7 times on each session | up to 2 hours | |
Other | Heart rate | Assessed 7 times on each session | up to 2 hours | |
Other | Respiratory rate | Assessed 7 times on each session | up to 2 hours | |
Other | Oxygen saturation | Assessed 7 times on each session | up to 2 hours | |
Other | Plasma level of C-reactive protein (CRP) | Assessed 2 times on each session | up to 2 hours | |
Other | Plasma level of cortisol | Assessed 2 times on each session | up to 2 hours | |
Other | Plasma level of brain derived neurotrophic factor | Assessed 2 times on each session | up to 2 hours | |
Other | Plasma level of glucose | Assessed 2 times on each session | up to 2 hours | |
Other | Plasma level of total cholesterol | Assessed 2 times on each session | up to 2 hours | |
Other | Plasma level of urea | Assessed 2 times on each session | up to 2 hours | |
Other | Plasma level of creatinine | Assessed 2 times on each session | up to 2 hours | |
Other | Plasma level of aspartate transaminase (AST) | Assessed 2 times on each session | up to 2 hours | |
Other | Plasma level of alanine transaminase (ALT) | Assessed 2 times on each session | up to 2 hours | |
Other | Evaluate the subjective effects of DMT | Assessment of the acute subjective effects of DMT, by 5D-ASC (5 Dimensions - Altered States of consciousness). Scores range from 0 to 94, where higher scores indicate more intense psychedelic subjective effects. | up to 2 hours | |
Other | Evaluate the mystical effects of DMT | Assessment of the acute subjective effects of DMT, by MEQ (Questionnaire of Mystical Experiences). Scores range from 0 to 150, where higher scores indicate more intense psychedelic subjective effects. | up to 2 hours | |
Other | Evaluate the influence of expectations on improvement in depressive symptoms | Assessment of the influence of patient's expectations on improvement in depressive symptoms as measured by a 5 point likert scale range from: nothing to extreme. | up to 0.5 hours | |
Other | Evaluate the influence of personality trait, by BFI (Big Five Inventory) | Assessment of the influence of personality trait assessed by the 44-item Big Five Inventory that measures an individual on the Big Five Factors (dimensions) of personality on depressive symptoms. The 5 dimensions are: Extraversion vs. introversion; Agreeableness vs. antagonism; Conscientiousness vs. lack of direction; Neuroticism vs. emotional stability; Openness vs. closedness to experience. | up to 3 months | |
Primary | Change in MADRS scores | Change in MADRS scores from baseline to 7 days after the dosing session. The Montgomery and Asberg Depression Rating Scale (MADRS) is in portuguese and has 10 items, with an overall score ranging from 0 to 60 points. Higher score indicates more severe depression. | 7 days | |
Secondary | Change in PHQ-9 scores | Change in PHQ-9 scores from baseline to 7 days after the dosing session. The Patient Health Questionnaire-9 (PHQ-9) is a questionnaire self-reported assessing the severity of the depression. The scale was in french and has 9 items, with an overall score ranging from 0 to 27 points. Higher score indicates more severe depression. | 7 days | |
Secondary | Change in BSI scores. | Change in BSI scores from baseline to 1 day after the dosing session. The Beck rating scale for suicidal ideation (BSI) is a 21-item self-report questionnaire. Each item is rated on a scale from 0 to 2, resulting in a total score ranging from 0 to 38. | 1 day | |
Secondary | Change in MADRS scores 14 days | Change in MADRS scores from baseline to 14 day after the dosing session. The Montgomery and Asberg Depression Rating Scale (MADRS) is in portuguese and has 10 items, with an overall score ranging from 0 to 60 points. Higher score indicates more severe depression. | 14 days | |
Secondary | Change in MADRS scores 1 month | Change in MADRS scores from baseline to one month after the dosing session. The Montgomery and Asberg Depression Rating Scale (MADRS) is in portuguese and has 10 items, with an overall score ranging from 0 to 60 points. Higher score indicates more severe depression. | 1 month | |
Secondary | Change in MADRS scores 3 months | Change in MADRS scores from baseline to three months after the dosing session. The Montgomery and Asberg Depression Rating Scale (MADRS) is in portuguese and has 10 items, with an overall score ranging from 0 to 60 points. Higher score indicates more severe depression. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01316926 -
Paxil CR Bioequivalence Study Brazil
|
Phase 1 | |
Recruiting |
NCT06187454 -
Transcranial Direct Current Stimulation for Depression
|
N/A | |
Completed |
NCT04469322 -
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
|
N/A | |
Recruiting |
NCT05768126 -
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
|
Phase 4 | |
Completed |
NCT03219879 -
Telephone-administered Relapse Prevention for Depression
|
N/A | |
Recruiting |
NCT06038721 -
Unified Protocol: Community Connections
|
N/A | |
Completed |
NCT03043560 -
Study to Treat Major Depressive Disorder With a New Medication
|
Phase 2 | |
Completed |
NCT04091139 -
Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong
|
Phase 2/Phase 3 | |
Completed |
NCT00069459 -
Seasonal Affective Depression (SAD) Study
|
Phase 1 | |
Recruiting |
NCT05503966 -
Combining Antidepressants and Attention Bias Modification in Depression
|
N/A | |
Recruiting |
NCT03001245 -
Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents
|
N/A | |
Completed |
NCT02939560 -
TMS for Adults With Autism and Depression
|
N/A | |
Completed |
NCT02542891 -
European Comparative Effectiveness Research on Internet-based Depression Treatment
|
N/A | |
Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
Withdrawn |
NCT02238730 -
Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy
|
N/A | |
Completed |
NCT02306551 -
Well Being And Resilience: Mechanisms of Transmission of Health and Risk
|
||
Completed |
NCT02224508 -
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
|
N/A | |
Completed |
NCT01407575 -
Buprenorphine for Treatment Resistant Depression
|
Phase 3 | |
Completed |
NCT01597661 -
Bupropion & Cardio Birth Defect (Slone)
|
N/A | |
Completed |
NCT01093053 -
Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations
|
N/A |